Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

被引：464

作者：

Drygin, Denis ^{[1
]}

Siddiqui-Jain, Adam ^{[1
]}

O'Brien, Sean ^{[1
]}

Schwaebe, Michael ^{[1
]}

Lin, Amy ^{[1
]}

Bliesath, Josh ^{[1
]}

Ho, Caroline B. ^{[1
]}

Proffitt, Chris ^{[1
]}

Trent, Katy ^{[1
]}

Whitten, Jeffrey P. ^{[1
]}

Lim, John K. C. ^{[1
]}

Von Hoff, Daniel ^{[2
]}

Anderes, Kenna ^{[1
]}

Rice, William G. ^{[1
]}

机构：

[1] Cylene Pharmaceut Inc, San Diego, CA 92121 USA

[2] Translat Genom Res Inst, Phoenix, AZ USA

来源：

CANCER RESEARCH | 2009年 / 69卷 / 19期

关键词：

POLYMERASE-I TRANSCRIPTION; QUADRUPLEX LIGAND RHPS4; CELL-PROLIFERATION; C-MYC; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; HUMAN GENOME; G4; DNA; CANCER; NUCLEOLIN;

D O I：

10.1158/0008-5472.CAN-09-1304

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hallmark deregulated signaling in cancer cells drives excessive ribosome biogenesis within the nucleolus, which elicits unbridled cell growth and proliferation. The rate-limiting step of ribosome biogenesis is synthesis of rRNA (building blocks of ribosomes) by RNA Polymerase I (Pol I). Numerous kinase pathways and products of proto-oncogenes can up-regulate Pol 1, whereas tumor suppressor proteins can inhibit rRNA synthesis. In tumorigenesis, activating mutations in certain cancer-associated kinases and loss-of-function mutations in tumor suppressors lead to deregulated signaling that stimulates Pol I transcription with resultant increases in ribosome biogenesis, protein synthesis, cell growth, and proliferation. Certain anticancer therapeutics, such as cisplatin and 5-fluorouracil, reportedly exert, at least partially, their activity through disruption of ribosome biogenesis, yet many prime targets for anticancer drugs within the ribosome synthetic machinery of the nucleolus remain largely unexploited. Herein, we describe CX-3543, a small molecule nucleolus-targeting agent that selectively disrupts nucleolin/rDNA G-quadruplex complexes in the nucleolus, thereby inhibiting Pol I transcription and inducing apoptosis in cancer cells. CX-3543 is the first C-quadruplex interactive agent to enter human clinical trials, and it is currently under evaluation against carcinoid/neuroendocrine tumors in a phase 11 clinical trial. [Cancer Res 2009;69(19):7653-61]

引用

页码：7653 / 7661

页数：9

共 57 条

[21] Genomic distribution and functional analyses of potential G-quadruplex-forming sequences in Saccharomyces cerevisiae [J].